Clinical trial NCT00290485 - References

Gastrointestinal Stromal Tumors — Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)

Citation(s)

•   Blanke CD, Eisenberg BL, Heinrich MC
  Gastrointestinal stromal tumors. Curr Treat Options Oncol. 2001 Dec;2(6):485-91. Review.
•   Bono P, Krause A, von Mehren M, Heinrich MC, Blanke CD, Dimitrijevic S, Demetri GD, Joensuu H
  Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood. 2004 Apr 15;103(8):2929-35. Epub 2004 Jan 8.
•   Bümming P, Andersson J, Meis-Kindblom JM, Klingenstierna H, Engström K, Stierner U, Wängberg B, Jansson S, Ahlman H, Kindblom LG, Nilsson B
  Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer. 2003 Aug 4;89(3):460-4.
•   Connolly EM, Gaffney E, Reynolds JV
  Gastrointestinal stromal tumours. Br J Surg. 2003 Oct;90(10):1178-86. Review.
•   Crosby JA, Catton CN, Davis A, Couture J, O'Sullivan B, Kandel R, Swallow CJ
  Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol. 2001 Jan-Feb;8(1):50-9.
•   DeMatteo RP
  The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol. 2002 Nov;9(9):831-9. Review.
•   Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H
  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002 Aug 15;347(7):472-80.
•   Eisenberg BL
  Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors. Oncology (Williston Park). 2003 Nov;17(11):1615-20; discussion 1620, 1623, 1626 passim. Review.
•   Frolov A, Chahwan S, Ochs M, Arnoletti JP, Pan ZZ, Favorova O, Fletcher J, von Mehren M, Eisenberg B, Godwin AK
  Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther. 2003 Aug;2(8):699-709.
•   Greenson JK
  Gastrointestinal stromal tumors and other mesenchymal lesions of the gut. Mod Pathol. 2003 Apr;16(4):366-75. Review.
•   Joensuu H
  Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec). Med Klin (Munich). 2002 Jan 15;97 Suppl 1:28-30.
•   Judson I
  Gastrointestinal stromal tumours (GIST): biology and treatment. Ann Oncol. 2002;13 Suppl 4:287-9. Review.
•   Kanda T, Ohashi M, Makino S, Kaneko K, Matsuki A, Nakagawa S, Hatakeyama K
  A successful case of oral molecularly targeted therapy with imatinib for peritoneal metastasis of a gastrointestinal stromal tumor. Int J Clin Oncol. 2003 Jun;8(3):180-3.
•   Kitamura Y, Hirota S, Nishida T
  Gastrointestinal stromal tumors (GIST): a model for molecule-based diagnosis and treatment of solid tumors. Cancer Sci. 2003 Apr;94(4):315-20. Review. Erratum in: Cancer Sci. 2003 Oct;94(10):930.
•   Kovac D, Petrovecki M, Jasic M, Dobi-Babic R, Ivanis N, Rubinic M, Krizanac S, Jonjic N, Rizzardi C, Melato M
  Prognostic factors of gastrointestinal stromal tumors. Anticancer Res. 2002 May-Jun;22(3):1913-7.
•   Liberati G, Lucchetta MC, Petraccia L, Nocchi S, Rosentzwig R, De Matteis A, Grassi M
  [Meta-analytical study of gastrointestinal stromal tumors (GIST)]. Clin Ter. 2003 Mar-Apr;154(2):85-91. Italian.
•   Miettinen M, Lasota J
  Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol. 2003;54(1):3-24. Review.
•   Noguchi T, Sato T, Takeno S, Uchida Y, Kashima K, Yokoyama S, Müller W
  Biological analysis of gastrointestinal stromal tumors. Oncol Rep. 2002 Nov-Dec;9(6):1277-82.
•   Patel SR
  Systemic therapy for advanced soft-tissue sarcomas. Curr Oncol Rep. 2002 Jul;4(4):299-304.
•   Radford IR
  Imatinib. Novartis. Curr Opin Investig Drugs. 2002 Mar;3(3):492-9. Review.
•   Rajput A, Kraybill WG
  Clinical trials and soft tissue sarcomas. Surg Oncol Clin N Am. 2003 Apr;12(2):485-97. Review.
•   Rosai J
  GIST: an update. Int J Surg Pathol. 2003 Jul;11(3):177-86. Review.
•   Rossi CR, Mocellin S, Mencarelli R, Foletto M, Pilati P, Nitti D, Lise M
  Gastrointestinal stromal tumors: from a surgical to a molecular approach. Int J Cancer. 2003 Nov 1;107(2):171-6. Review.
•   Schirru A, Cavaliere D, Cosce U, Scarimbolo M, Griseri G, Caristo I, Bianchi M, Ingravaglieri E, Aiello D, Venturino E
  [Surgical treatment of gastrointestinal stromal tumors: personal cases]. Tumori. 2003 Jul-Aug;89(4 Suppl):141-2. Review. Italian.
•   Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA, Demetri GD
  STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001 Aug 16;20(36):5054-8.
•   Yan H, Marchettini P, Acherman YI, Gething SA, Brun E, Sugarbaker PH
  Prognostic assessment of gastrointestinal stromal tumor. Am J Clin Oncol. 2003 Jun;26(3):221-8.

A Phase II Study on Preoperative Administration of Gleevec in Patients With Initially Non-Resectable Gastrointestinal Stromal Tumor

Details for clinical trial NCT00290485